Replies to post #202407 on Biotech Values

[DewDiligence]

ADXS/AZN complete second dosing cohort in phase-1/2 combination study of ADXS-HPV and durvalumab (anti-PD-L1) in cervival and H&N cancer:

http://finance.yahoo.com/news/phase-1-2-combination-trial-120000742.html